Program
olatorepatide
Also written as “Olatorepatide”, “HS-20094” and “HS-20094 Injection”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hidradenitis Suppurativa · Overweight, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 83 open or running | phase 3since Feb 18, 2025 | Oct 29, 2021 | Mar 30, 2027phase 3 · NCT07156500 |
| Regeneron Pharmaceuticals | 44 open or running | phase 3since Oct 19, 2026 | Feb 18, 2026 | Jan 21, 2028phase 2 · NCT07685808 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
Olatorepatide (HS-20094)
, phase 4, as of Aug 26, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseRegeneron licensed it from Hansoh, for everywhere outside mainland China, Hong Kong and Macau.Announced Jun 2, 2025 · Source: Regeneron, Jun 2, 2025
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 29, 2021First study: phase 1 study in Diabetes Mellitus, Type 2New to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT05116410 · 68 enrolled · China
- May 25, 2023Phase 2 study in Diabetes Mellitus, Type 2Hansoh Pharmaceutical Group · NCT06118008 · 54 enrolled · China
- Oct 17, 2023Phase 2 study in OverweightHansoh Pharmaceutical Group · NCT06118021 · 200 enrolled · China
- Feb 18, 2025Phase 3 study in OverweightHansoh Pharmaceutical Group · NCT06839664 · 604 enrolled · China
- Feb 25, 2025Phase 2 study in Diabetes Mellitus, Type 2Hansoh Pharmaceutical Group · NCT06901648 · 275 enrolled · China
- Jun 2, 2025Phase 1 study in OverweightHansoh Pharmaceutical Group · NCT07057674 · 144 planned · China
- Aug 28, 20252 phase 3 studies in Diabetes Mellitus, Type 2Hansoh Pharmaceutical Group · NCT07156539, NCT07156500
- Feb 18, 2026Regeneron Pharmaceuticals's first study: phase 2 study in OverweightNew to Regeneron PharmaceuticalsRegeneron Pharmaceuticals · NCT07431086 · 120 enrolled · United States
- Jun 29, 2026Phase 2 study in OverweightRegeneron Pharmaceuticals · NCT07685808 · 360 planned · United States
- Sep 15, 2026Phase 2 study in Hidradenitis SuppurativaRegeneron Pharmaceuticals · NCT07830329 · 300 planned · United States
- Oct 19, 2026Phase 3 study in OverweightPhase 3 reachedRegeneron Pharmaceuticals · NCT07896265 · 3,000 planned
Ahead
- Nov 13, 2026Primary completion: phase 2 study in OverweightRegeneron Pharmaceuticals · NCT07431086
- Mar 30, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Hansoh Pharmaceutical Group · NCT07156539
- Mar 30, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Hansoh Pharmaceutical Group · NCT07156500
- Jan 21, 2028Primary completion: phase 2 study in OverweightRegeneron Pharmaceuticals · NCT07685808
TargetBeta
“A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity Without Diabetes (RISE-1)”study text, read by Claude · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| enicepatide | Hoffmann-La Roche | phase 3 | 10 |
| VK2735rule | Viking Therapeutics | phase 3 | 8 |
| NNC0519-0130 | Novo Nordisk | phase 2 | 11 |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 6 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
| NA-931rule | biomed-industries-inc | phase 2 | 3 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07896265Overweight | 3 | Not yet recruiting | Regeneron Pharmaceuticals | Dec 19, 2028 | 3,000 |
| NCT07830329Hidradenitis Suppurativa · United States | 2 | Recruiting | Regeneron Pharmaceuticals | Nov 24, 2028 | 300 |
| NCT07685808Overweight · United States | 2 | Recruiting | Regeneron Pharmaceuticals | Jan 21, 2028 | 360 |
| NCT07431086Overweight · United States | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Nov 13, 2026 | 120 |
| NCT07156539Diabetes Mellitus, Type 2 · China | 3 | Not yet recruiting | Hansoh Pharmaceutical Group | Mar 30, 2027 | 546 |
| NCT07156500Diabetes Mellitus, Type 2 · China | 3 | Not yet recruiting | Hansoh Pharmaceutical Group | Mar 30, 2027 | 204 |
| NCT07057674Overweight · China | 1 | Recruiting | Hansoh Pharmaceutical Group | Feb 4, 2026 | 144 |
| NCT06901648Diabetes Mellitus, Type 2 · China | 2 | Completed | Hansoh Pharmaceutical Group | Mar 7, 2025 | 275 |
| NCT06839664Overweight · China | 3 | Completed | Hansoh Pharmaceutical Group | Jan 4, 2026 | 604 |
| NCT06118021Overweight · China | 2 | Completed | Hansoh Pharmaceutical Group | Aug 13, 2024 | 200 |
| NCT06118008Diabetes Mellitus, Type 2 · China | 2 | Completed | Hansoh Pharmaceutical Group | Jan 4, 2024 | 54 |
| NCT05116410Diabetes Mellitus, Type 2 · China | 1 | UNKNOWN | Hansoh Pharmaceutical Group | Oct 31, 2022 | 68 |
How it is read
Names in the registry
- “Olatorepatide”, 4 entries
- “HS-20094”, 3 entries
- “HS-20094 Injection”, 3 entries
- “HS-20094 injection”, 1 entry
- “HS-20094 5mg”, 1 entry
Codes read as this program: HS20094.
Conditions, from the studies’ own filings
- Obesity, 5 studies
- Diabetes Mellitus, Type 2, 5 studies
- Hidradenitis Suppurativa, 1 study
- Overweight, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.